IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2295-2305

  Yang, Yuzhe ^a,b   Yee, Douglas ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINO ACID TRANSPORTER; AMINO ACID TRANSPORTER MOLECULE XC; ESTROGEN RECEPTOR; GLUTATHIONE; INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; NVP AEW 541; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MCF 7 CELL LINE; OVERALL SURVIVAL; OXIDATION REDUCTION STATE; PRIORITY JOURNAL;

AMINO ACID TRANSPORT SYSTEM Y+; BREAST NEOPLASMS; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYSTINE; DOWN-REGULATION; FEMALE; GLUTATHIONE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MCF-7 CELLS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84899536351     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1803     Document Type: Article

References (36)

1. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001;8:197-209.
2. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.
3. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006;7:85-96.
4. Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor- I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 1998;273:9994-10003.
5. Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulinlike growth factor receptor activation in breast cancer cells. Br J Cancer 2006;95:1220-8.
6. Jackson JG, Zhang X, Yoneda T, Yee D. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 2001;20:7318-25.
7. Kaufman PA,Ferrero JM,Bourgeois H,Kennecke H,DeBoer R, JacotW, et al. A Randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res 2010;70:55-63.
8. Yang Y, Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2012;17:251-61.
9. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012;104:975-81.
10. Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 2008;215:593-602.
11. Vaughn AE, Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol 2008;10:1477-83.
12. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, et al. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied Breceptors are switched to transcriptional agonists by cAMP. Cancer Res 1994;54:3868-77.
13. Trachootham D, Alexandre J, Huang P. Targeting cancer cells byROSmediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-91.
14. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
15. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011;19:387-400.
16. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell survival. Antioxidants Redox Signal 2008;10:1343-74.
17. Schneider BL, Kulesz-MartinM. Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. Carcinogenesis 2004;25: 2033-44.
18. Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, Kralli A, et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 2007;67:1472-86.
19. Sullivan R, Graham CH. Chemosensitization of cancer by nitric oxide. Curr Pharm Des 2008;14:1113-23.
20. Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, et al. Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem 2005;280:37423-9.
21. Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene 2009;28:599-609.
22. Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 2005;65:7446-54.
23. Pham AN, Blower PE, Alvarado O, Ravula R, Gout PW, Huang Y. Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. J Pharmacol Exp Ther 2010;332:949-58.
24. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 2012;72:3372-80.
25. Oncomine [database on the Internet]. Available from: www.oncomine. org.
26. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999;13: 787-96.
27. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Br Cancer Res Treat 2010;123:725-31.
28. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979;254:7558-60.
29. Leach JK, Van Tuyle G, Lin PS, Schmidt-Ullrich R, Mikkelsen RB. Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. Cancer Res 2001;61:3894-901.
30. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-Acetylcysteine actions. Cell Mol Life Sci: CMLS 2003;60:6-20.
31. Wiemer EA. Stressed tumor cell, chemosensitized cancer. Nat Med 2011;17:1552-4.
32. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Br Cancer Res: BCR 2006;8:R59.
33. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 2013;24:450-65.
34. Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 2013;73:4383-94.
35. Koglin N, Mueller A, Berndt M, Schmitt-Willich H, Toschi L, Stephens AW, et al. Specific PET imaging of xC- transporter activity using a (1)(8) F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism. Clin Cancer Res 2011;17:6000-11.
36. Baek S, Choi CM, Ahn SH, Lee JW, Gong G, Ryu JS, et al. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res 2012;18: 5427-37.